China Pharma Holdings (CPHI) EV to EBITDA (2010 - 2026)

China Pharma Holdings (CPHI) has reported EV to EBITDA for 17 consecutive years, with 18.47 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBITDA fell 130.95% year-over-year to 18.47; the trailing twelve-month figure through Jun 2026 stood at 6.04 (down 327.69% YoY), and the FY2025 full-year result was 1.5, down 100.02% from the prior year.
• EV to EBITDA slipped to 18.47 in Q2 2026 per CPHI's latest filing, from 13.83 in the prior quarter.
• Across five years, EV to EBITDA topped out at 0.53 in Q4 2023 and bottomed at 18.47 in Q2 2026.
• Historically, EV to EBITDA has averaged 7.1 across 5 years, with a median of 5.22 in 2024.
• The sharpest annual moves came in 2022 and 2024: EV to EBITDA jumped 90.71% in 2022, then sank 445.6% in 2024.
• Over 5 years, EV to EBITDA stood at 2.58 in 2022, then surged by 79.57% to 0.53 in 2023, then sank by 445.6% to 2.87 in 2024, then tumbled by 40.7% to 4.04 in 2025, then plunged by 357.19% to 18.47 in 2026.
• According to Business Quant data, EV to EBITDA over the past three periods registered 18.47, 13.83, and 4.04 for Q2 2026, Q1 2026, and Q4 2025 respectively.